El interés en corto de Tungray Technologies da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tungray Technologies. Los datos de interés en corto se actualizan cada dos semanas.

Tungray Technologies (NASDAQ:TRSG) Bolsa, Informe de interés en corto

Tungray Technologies

Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.

Tungray Technologies Inc - Class A Ordinary Shares

Tungray Technologies Inc

&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

News

SNGX

Soligenix Announces That is Successfully Manufactured Synthetic Hypericin At Sterling Pharma Solutions

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive's clonoSEQ&#xAE; test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR&#xAE;, Flatiron's cloud-based Electronic Medical Record (EMR) platform.
Integrating clonoSEQ within OncoEMR simplifies and accelerates access to MRD testing to over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S. This integration enables providers to order and review clonoSEQ MRD testing results directly within the EMR, leading to more efficient testing workflows and increasing real-time insights into the patient's disease status.
This integration will be effective as of today, July 1, 2025, to all OncoEMR's MPI users. clonoSEQ will continue to be available to providers outside the Flatiron network through a rapidly expanding number of other EMR integrations and via Adaptive's online diagnostic portal.
 &nbsp;

ADPT

Adaptive Biotechnologies Integrates Adaptive's clonosSEQ Test For MRD Assessment In Lymphoid Malignancies Into OncoEMR, Flatiron's Cloud-Based EMR Platform

Biotech

General

CGTX

Cognition Therapeutics Study Of Zervimesine (CT1812) For Early Alzheimer's Disease Surpasses 50% Enrollment Target

Financing

AMC Enters Transaction Support Agreement With Creditor Groups; Includes ~$223.3M Of New Money Financing, Immediate Conversion Of $143.0M Of 6.00%/8.00% Senior Secured Exchangeable Notes due 2030 And Resolution Of Litigation With Certain Holders Of 7.5% Senior Secured Notes due 2029

Canaccord Genuity analyst Richard Close initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Buy rating and announces Price Target of $27.

Price Target

Initiation

Analyst Ratings

OMDA

Canaccord Genuity Initiates Coverage On Omada Health with Buy Rating, Announces Price Target of $27

QMCO: -15% &#x7C; <a href="https://www.benzinga.com//node/46181747">Quantum shares are trading lower after the company delayed its FY25 10-K filing due to an ongoing review of its accounting.</a>
&nbsp;
CLRO: 140% &#x7C; <a href="https://www.benzinga.com//node/46182384">ClearOne Declares One-Time Special Stock Dividend On The Co's Issued And Outstanding Shares Of Common Stock And Any Common Stock Equivalents With Dividend Rights To Legacy Stockholders With A 100% Stake In The Proceeds From Any Eventual Sale Of All Or Substantially All Of The Co's Current Assets And Operations In One Or More Transactions</a>
&nbsp;
GPUS: 117% &#x7C; <a href="https://www.benzinga.com//node/46190175">Hyperscale Data's Ault Markets Plans To Launch Decentralized Cryptocurrency Exchange To Be Based In US, With Headquarters In Las Vegas, Nevada</a>

Movers

Trading Ideas

CLRO

GPUS

QMCO

Market-Moving News for July 1st

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock. Nektar is selling 4,255,320 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $23.50 per share. The gross proceeds to Nektar from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional 638,298 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.&nbsp;All of the securities being sold in this offering are being offered by Nektar. The offering is expected to close on July 2, 2025, subject to the satisfaction of customary conditions.
Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development and manufacturing costs to support the advancement of its drug candidates, as well as other general corporate purposes.
 &nbsp;

Offerings

NKTR

Nektar Therapeutics Prices Underwritten Public Offering Of $100M Of Shares At $23.50/Shr

Nouveau Monde Graphite Pays Q2 2025 Accrued Interest To Investissement Québec via Share Issuance

UK's CMA Considering Whether Global Payments / Worldpay Merger Will Reduce Competition Within Any Market

Pursuant to the Agreement and subject to the completion of certain closing procedures, the investor has agreed to exchange approximately $28 million in outstanding Senior Notes, consisting of $8 million in December 2026 notes, $2 million in January 2028 notes, and $18 million in August 2028 notes, for $13 million in newly issued 8.00% Senior Secured Second Lien Notes due January 1, 2028 (the "Notes"). In addition, the Company is issuing to the investor warrants to purchase an aggregate of approximately 52,000 common shares at an exercise price of&nbsp;$10.00&nbsp;per share. The warrants are exercisable for a period of seven years from the issuance date.

RILY

B. Riley Financial Reduces Total Outstanding Debt by ~$15M Through Private Bond Exchange Agreement

Ark Invest, a leading investment management firm led by Cathie Wood, has highlighted a pivotal development set to bridge the world of blockchain-based capital with the substantial U.S. mortgage market.
What Happened: According to Nick Grous, an associate portfolio manager at Ark Invest, the recent directive from the Federal Housing Finance Agency (FHFA) instructing Fannie Mae (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FNMA#OTC">FNMA</a>) and Freddie Mac (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FMCC#OTC">FMCC</a>) to consider cryptocurrency holdings, such as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), for mortgage loan risk assessments marks &#8220;crypto's first step into U.S. housing: from wallets to mortgages.&#8221;
&#8220;This directive introduces a novel bridge between blockchain-based capital and the $12 trillion U.S. mortgage market,&#8221; Grous notes.
Looking at the potential scale, Grous references iEmergent's 2024 Home Mortgage Disclosure Act (HMDA) data, which reported around &#8220;6 million mortgage originations in the U.S. last year, valued at $1.82 trillion.&#8221;
Based on an average loan size of approximately &#8220;$340,000,&#8221; Ark Invest&#8217;s analysis suggests that &#8220;if just 5% of mortgage borrowers included crypto-based assets in their applications, ~305,000 would qualify for a mortgage in this new framework—supporting $100 billion in originations.&#8221;
He further projects that &#8220;each additional percentage point of adoption would increase mortgage loan volume by ~$20 billion.&#8221;
This regulatory development, according to Ark Invest, &#8220;aligns with ARK's thesis that crypto will reshape legacy financial systems with greater transparency, automation, and interoperability.&#8221;
See Also: <a href="https://www.benzinga.com/crypto/25/06/46089173/michael-saylor-offers-btc-credit-model-as-bill-pulte-pushes-crypto-for-fannie-mae-freddie-mac-could-bitcoin-soon-count-toward-mortgage-qualification">Michael Saylor Offers BTC Credit Model As Bill Pulte Pushes Crypto For Fannie Mae, Freddie Mac: Could Bitcoin Soon Count Toward Mortgage Qualification? </a>
Why It Matters: The FHFA&#8217;s directive, issued last week, represents a significant shift.
It allows for the inclusion of cryptocurrency holdings, specifically &#8220;only those held on U.S.-regulated centralized exchanges,&#8221; as assets in single-family mortgage loan risk assessments.
Crucially, this directive &#8220;does not require converting crypto to U.S. dollars and does not include crypto held in self-custodied wallets.&#8221;
It also mandates &#8220;risk controls, like accounting for crypto market volatility and limiting how much crypto can count toward reserves,&#8221; signaling a cautious yet forward-looking approach to integration.
Last week, Strategy Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) Michael Saylor stepped forward to offer Strategy&#8217;s (formerly MicroStrategy) <a href="http://46089173/michael-saylor-offers-btc-credit-model-as-bill-pulte-pushes-crypto-for-fannie-mae-freddie-mac-could-bitcoin-soon-count-toward-mortgage-qualification">Bitcoin Credit Model</a> to support the initiative. 
Meanwhile, the Bitcoin Policy Institute <a href="https://www.btcpolicy.org/articles/the-powerful-fannie-mae-policy-change-to-unlock-bitcoin-based-mortgages">hails</a> this as a potential game-changer, stating that a tweak to Fannie Mae&#8217;s Selling Guide to recognize Bitcoin as collateral could unlock homeownership for millions, aligning with Donald Trump&#8217;s vision to make the U.S. the &#8220;Bitcoin Capital of the planet.&#8221;
Price Action: Fannie Mae shares ended 1.95% lower on Monday. It has risen by 177.33% on a year-to-date basis and 553.42% over the past year.
On the other hand, Freddie Mac declined 1.55% on Monday, and it has risen by 144.51% on a year-to-date basis and 505.88% over the past year.
After hitting fresh records on Friday and Monday, on Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket. The SPY was down 0.18% at $616.74, while the QQQ declined 0.26% to $550.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46189081/what-are-stock-tokens-and-how-to-trade-them-robinhoods-new-offering-merges-owning-stocks-with-blockchain-tech-heres-how-it-works">What Are Stock Tokens And How To Trade Them? Robinhood&#8217;s New Offering Merges Owning Stocks With Blockchain Tech: Here&#8217;s How It Works</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$ETH

FMCC

FNMA

MSTR

Bitcoin, Ethereum Could Soon Help You Get A Mortgage Now — Cathie Wood's Ark Invest Sees $12 Trillion Opportunity After FHFA Move

Cash proceeds will be allocated to debt repayment, resulting in a pro-forma leverage ratio below 2.0x after the closing, to be further reduced with the previously announced planned divestiture of Greif's timberland business. These actions will enable future disciplined capital redeployment and optionality for strategic growth investments.
Strategic Rationale:
<ul>
<li>Further Positions Greif as a Packaging Leader</li>
<li>Allows Greif to Deliver More Durable Earnings</li>
<li>Enhances Capital Utilization, Reducing Recurring Capital Needs</li>
<li>Enables Debt Reduction, Unlocking Value-Creation Opportunities</li>
</ul>

Greif To Sell Containerboard Unit And CorrChoice Network To Packaging Corporation Of America For $1.8B

YY Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) ("YY Group," "YYGH," or the "Company"), a global leader in on-demand workforce solutions and integrated facility management (IFM), is pleased to announce its acquisition of Pesticide Pest Control Pte. Ltd., a Singapore-based pest control company with over 30 years of operational history.
The company will be rebranded as Pest Fighter Management Pte. Ltd., marking the beginning of its next growth phase under YY Group's integrated IFM platform. The acquisition is expected to close on July 1, 2025.
Revenue Trajectory and Outlook
YY Group's integration of Pest Fighter is expected to contribute significantly to its growth trajectory. The Group projects annual revenue to increase from S$26.3 million in 2023 to S$96.0 million by 2028, representing a compound annual growth rate of 29.1% substantially outpacing industry averages of 5% to 8% annually.
Pest Fighter is anticipated to enhance client retention, strengthen the value of bundled services, and improve profit margins, further anchoring YY Group's ability to deliver comprehensive facility solutions.

YYGH

YY Group Acquires Pesticide Pest Control For Undisclosed Terms; Co To Be Rebranded As Pest Fighter Management Pte. Ltd.

Greif To Sell Containerboard Business to Packaging Corp. for $1.8B in All-Cash Deal; Proceeds to Cut Debt, Sharpen Portfolio Focus

NIP Group Inc. ("NIPG" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>), a leading digital entertainment company, today announced it has entered into a definitive asset-purchase agreement (the "Agreement") to acquire on-rack crypto mining machines (the "Products") from Fortune Peak Limited and Apex Cyber Capital Limited (together, the "Sellers"). These Products are currently used for Bitcoin mining and are expected to begin generating significant Bitcoin mining revenue for the Company upon closing of the acquisition. To support this initiative, NIPG has established a dedicated Digital Computing Division to manage the operations of the acquired Products and lead the future development of the Company's compute infrastructure capabilities. Importantly, this transaction marks a strategic extension of NIPG's business into the digital infrastructure space.
The Products, consisting of data center capacity with a combined hash rate of 3.11 EH/s, are currently utilized for Bitcoin mining operations with expected production of approximately 60 Bitcoins per month, and will continue operating immediately after closing of the proposed transaction. Under the terms of the Agreement, NIPG will pay the consideration for the Products through issuance of approximately 119,553,439 Class A ordinary shares of the Company to the Sellers. In connection with the consummation of the proposed transactions contemplated by the Agreement, the Company and the Sellers will also enter into an investor rights agreement to define certain rights and obligations among them with respect to the Company.
The closing of the proposed transaction is expected to occur on or before September 30, 2025, and is subject to customary closing conditions. There can be no assurance that the closing conditions will be satisfied nor that the proposed transaction will be completed before that date or at all.

NIPG

NIP Group to Acquire Bitcoin Mining Machines, Expands Into Digital Infrastructure

Rosenblatt analyst Kevin Cassidy maintains Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Neutral and maintains $3 price target.

BZAI

Rosenblatt Maintains Neutral on Blaize Holdings, Maintains $3 Price Target

Investar Holding Corporation ("Investar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISTR#NASDAQ">ISTR</a>), the holding company for Investar Bank, N.A., and Wichita Falls Bancshares, Inc. ("Wichita Falls"), the holding company for First National Bank, Wichita Falls, Texas, jointly announced today that they have entered into a definitive agreement pursuant to which Investar will acquire Wichita Falls for cash and stock consideration. In connection with the proposed acquisition, Investar also announced today a private placement of $32.5 million of its newly designated 6.5% Series A Non-Cumulative Perpetual Convertible Preferred Stock.
The definitive agreement has been unanimously approved by the boards of directors of Investar and Wichita Falls, and the closing of the transaction, which is expected to occur in the fourth quarter of 2025, is subject to customary conditions, including shareholder and regulatory approvals. The definitive agreement provides that upon the closing of the transaction, Wichita Falls shareholders will be entitled to receive an aggregate of 3,955,334 shares of Investar common stock, and cash consideration of $7.2 million, in exchange for their shares, subject to adjustment under certain circumstances. Based on the closing price of $19.32 for Investar common stock on June 30, 2025, the transaction would result in aggregate consideration of approximately $83.6 million, or $134.67 per share of Wichita Falls common stock.
&nbsp;

ISTR

Investar Holding Corporation Announced Merger with Wichita Falls Bancshares

PSEC

Prospect Capital Closes $115M All-Cash Acquisition Of QC Holdings; Company To Remain Headquartered In Kansas Under Existing Leadership

BLCO

Bausch + Lomb Uses Survey Insights And Patient Input To Clarify Dry Eye Realities

Adagene Inc. ("Adagene or the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise by Sanofi (Euronext: SAN FP).
Sanofi has agreed to make strategic investment of up to US$25 million in Adagene. The Company plans to use the proceeds to fund its research and development activities, including clinical development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody, through a randomized phase 2 trial in microsatellite stable colorectal cancer (MSS CRC).
To further explore the clinical potential of muzastotug, Adagene will supply Sanofi with muzastotug to evaluate the safety, efficacy, pharmacokinetics and biomarker data in combination with other anticancer therapies in over 100 patients in a phase 1/2 clinical trial in advanced solid tumors. Adagene continues to own worldwide commercial rights to muzastotug.
Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene's proprietary masking technology and antibody engineering expertise. The bispecific therapeutic, with undisclosed targets, will be engineered by Adagene and induces an option exercise fee, as well as milestones and royalties as per the 2022 partnership agreement with Adagene.

ADAG

Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials

Press Releases

TRSG Investor News: Rosen Law Firm Encourages Tungray Technologies Inc Investors to Inquire About Securities Class Action Investigation - TRSG

TRSG Investor News: If You Have Suffered Losses in Tungray Technologies Inc (NASDAQ: TRSG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

TRSG Announcement: If You Have Suffered Losses in Tungray Technologies Inc (NASDAQ: TRSG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Comments

Tungray Technologies

Interés en corto

Tungray Technologies (NASDAQ:TRSG) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL